KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Deferred Charges (2017 - 2018)

Biomarin Pharmaceutical (BMRN) has disclosed Amortization - Deferred Charges for 5 consecutive years, with $1.0 million as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Amortization - Deferred Charges rose 13.54% year-over-year to $1.0 million, compared with a TTM value of $1.5 million through Jun 2018, up 13.58%, and an annual FY2018 reading of $3.6 million, down 3.09% over the prior year.
  • Amortization - Deferred Charges was $1.0 million for Q2 2018 at Biomarin Pharmaceutical, up from $886000.0 in the prior quarter.
  • Across five years, Amortization - Deferred Charges topped out at $1.0 million in Q2 2018 and bottomed at -$1.2 million in Q4 2014.
  • Average Amortization - Deferred Charges over 4 years is $463400.0, with a median of $828000.0 recorded in 2014.
  • The sharpest move saw Amortization - Deferred Charges plummeted 2824.44% in 2014, then grew 13.54% in 2018.
  • Year by year, Amortization - Deferred Charges stood at -$1.2 million in 2014, then skyrocketed by 167.13% to $823000.0 in 2015, then increased by 7.65% to $886000.0 in 2017, then rose by 13.54% to $1.0 million in 2018.
  • Business Quant data shows Amortization - Deferred Charges for BMRN at $1.0 million in Q2 2018, $886000.0 in Q2 2017, and $823000.0 in Q3 2015.